NCT04891185终止2 期
Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Rate of correct visualisation during debulking surgery with the near-infrared (NIR) fluorescence camera of peritoneal lesions of EOC in vivo by utilising ICG.
研究概览
简要总结
Visualise peritoneal lesions of epithelial ovarian cancer (EOC) in both primary and interval debulking surgery by using intravascular indocyanine green (ICG) and near-infrared (NIR) light. This Trial wants to investigate whether ICG can increase the visibility of peritoneal lesions and can differentiate between peritoneal implants and fibrosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
- •At least 18 years of age.
- •Advanced stage epithelial ovarian cancer: FIGO stage IIIb, IIIc or IV. (For FIGO staging classification, please refer to Appendix 7).
- •A biopsy or cytology confirming the presence of high-grade serous epithelial ovarian carcinoma
- •Preoperative imaging (CT and/or MRI), describing metastatic implants, as standard of care.
排除标准
- •Participant has a history of following diseases:
- •Hyperthyroidism
- •Autonomously functioning thyroid adenoma
- •Participant has an allergy or hypersensitivity for one or more of the following components:
- •Iodine (including potassium iodine)
- •Indocyanine green
- •Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
- •Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.
- •Participation in an interventional Trial with an investigational medicinal product (IMP) or device during the surgery itself.
- •Participant has a severe renal impairment (classified as renal function<30 ml/min/1,73m2 according to CKD-EPI).
- •Participant utilises sodium bisulfite-containing heparin preparations during the day before surgery. For Belgian registered drugs, this contains:
- •Danaparoid (Orgaran®)
- •Other low-molecular weight heparins registered in Belgium do not contain sodium bisulfite and are not an exclusion criterion.
- •Participants requires thyroid scintigraphy utilising radioactive iodine one week after surgery.
- •A previous history of major intra-abdominal surgery with potentially major adhesions and/or distorted anatomy.
- •Participants utilises one of the interacting drugs listed in the protocol
研究组 & 干预措施
Primary Debulking Surgery
Experimental
干预措施: Indocyanine green (Drug)
Interval Debulking Surgery
Experimental
干预措施: Indocyanine green (Drug)
结局指标
主要结局
Rate of correct visualisation during debulking surgery with the near-infrared (NIR) fluorescence camera of peritoneal lesions of EOC in vivo by utilising ICG.
时间窗: During debulking surgery
次要结局
- Percentage of lesions with positive correlation between pre-operative radiographic examination(s) and the ICG signal in vivo with the NIR fluorescence camera during surgery and immediately after surgery with the pathological examination.(During debulking surgery and immediately after debulking surgery, when the pathological examination report is available.)
- Rate of diagnostic accuracy during debulking surgery with the NIR fluorescence camera of peritoneal lesions of EOC in vivo by utilising ICG.(During debulking surgery)
- Obtaining the tumour-to-background ratio of fluorescence in peritoneal lesions, lymph nodes and other anatomical structures during debulking surgery by utilising still images captures with the NIR fluorescence camera.(During debulking surgery)
- Assessment of the number and type of adverse effects, severe adverse effects and adverse reactions with the trial dose of the IMP during and immediately after the surgery.(During debulking surgery and immediately after the surgery, up to the point in time when the pathological report is available.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
早期 1 期
Diagnostic Value of ICG in EndometriosisLaparoscopyNear Infrared Fluorescence ImagingIndocyanine Green (ICG)EndometriosisNCT03850158Insel Gruppe AG, University Hospital Bern63
进行中（未招募）
1 期
Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian CancerAdvanced stage high-grade serous epithelial ovarian cancer: FIGO stage IIIb, IIIc and IVMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002449-13-BEniversity Hospitals Leuven (UZ Leuven)40
Unknown
不适用
Peritoneal Carcinomatosis Extent Evaluation: Radiologic, Laparoscopic and Pathologic.Peritoneal CarcinomatosisNCT03798132Shimaa Abdalla Ahmed80
已完成
不适用
MicroFluO: FLUorescence-guided Surgery for Ovarian CancerOvarian CancerNCT05633836Assistance Publique - Hôpitaux de Paris3
Unknown
不适用
Intraoperative ICG Fluorescence Imaging for Peritoneal Carcinomatosis DetectionPeritoneal CarcinomatosisGastric CancerNCT04352894Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia120